218 related articles for article (PubMed ID: 27094677)
1. Identification of pyrazolopyridazinones as PDEδ inhibitors.
Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI
Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677
[TBL] [Abstract][Full Text] [Related]
2. Exploring binding modes of the selected inhibitors to phosphodiesterase delta by all-atom molecular dynamics simulations and free energy calculations.
Zhong H; Zhang YJ; Shan XB
J Biomol Struct Dyn; 2019 Jun; 37(9):2415-2429. PubMed ID: 30052144
[TBL] [Abstract][Full Text] [Related]
3. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of the association and dissociation of Deltarasin from the heterodimeric KRas4B-PDEδ complex.
Bello M; Correa-Basurto J; Vargas-Mejía MÁ
Biopolymers; 2019 Nov; 110(11):e23333. PubMed ID: 31568570
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H
Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361
[TBL] [Abstract][Full Text] [Related]
6. The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo.
Cruz-Nova P; Schnoor M; Correa-Basurto J; Bello M; Briseño-Diaz P; Rojo-Domínguez A; Ortiz-Mendoza CM; Guerrero-Aguirre J; García-Vázquez FJ; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
BMC Cancer; 2018 Nov; 18(1):1056. PubMed ID: 30382908
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
Cheng J; Li Y; Wang X; Dong G; Sheng C
J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
[TBL] [Abstract][Full Text] [Related]
8. An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit
Kaya P; Schaffner-Reckinger E; Manoharan GB; Vukic V; Kiriazis A; Ledda M; Burgos Renedo M; Pavic K; Gaigneaux A; Glaab E; Abankwa DK
J Med Chem; 2024 Jun; 67(11):8569-8584. PubMed ID: 38758695
[TBL] [Abstract][Full Text] [Related]
9. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
Zimmermann G; Schultz-Fademrecht C; Küchler P; Murarka S; Ismail S; Triola G; Nussbaumer P; Wittinghofer A; Waldmann H
J Med Chem; 2014 Jun; 57(12):5435-48. PubMed ID: 24884780
[TBL] [Abstract][Full Text] [Related]
10. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.
Dharmaiah S; Bindu L; Tran TH; Gillette WK; Frank PH; Ghirlando R; Nissley DV; Esposito D; McCormick F; Stephen AG; Simanshu DK
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6766-E6775. PubMed ID: 27791178
[TBL] [Abstract][Full Text] [Related]
12. Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.
Salmas RE; Mestanoglu M; Yurtsever M; Noskov SY; Durdagi S
Biophys J; 2015 Sep; 109(6):1163-8. PubMed ID: 26340817
[TBL] [Abstract][Full Text] [Related]
13. Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDEδ.
Ozdemir ES; Jang H; Gursoy A; Keskin O; Nussinov R
J Phys Chem B; 2018 Aug; 122(30):7503-7513. PubMed ID: 29961325
[TBL] [Abstract][Full Text] [Related]
14. Structure-based development of PDEδ inhibitors.
Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H
Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847
[TBL] [Abstract][Full Text] [Related]
15. PDEδ Binding to Ras Isoforms Provides a Route to Proper Membrane Localization.
Muratcioglu S; Jang H; Gursoy A; Keskin O; Nussinov R
J Phys Chem B; 2017 Jun; 121(24):5917-5927. PubMed ID: 28540724
[TBL] [Abstract][Full Text] [Related]
16. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells.
Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M
Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177
[TBL] [Abstract][Full Text] [Related]
17. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
Chen L; Zhuang C; Lu J; Jiang Y; Sheng C
J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity.
Leung ELH; Luo LX; Liu ZQ; Wong VKW; Lu LL; Xie Y; Zhang N; Qu YQ; Fan XX; Li Y; Huang M; Xiao DK; Huang J; Zhou YL; He JX; Ding J; Yao XJ; Ward DC; Liu L
Cell Death Dis; 2018 Feb; 9(2):216. PubMed ID: 29440631
[TBL] [Abstract][Full Text] [Related]
20. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity.
Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
